Review for 10.1186/s12876-018-0864-1 (2018)

Reviewer ’s report  
 
Title: The characteristics of nivolumab -induced colitis: an evaluation of three cases and a 
literature review  
 
Version: 1 Date: 25 Jun 2018  
 
Reviewer: Pavle Vrebalov C indro  
 
Reviewer's report:  
 
On page 3, in section Case 1 you stated that the patient had grade 3 diar rhea and that it was 
treated with mesalazine. In discussion you say that grade 3 should be treated with corticosteroids. 
Why was the patient not treated with corticosteroids? Other cases were treated with 
corticosteroids even those that were grade 2.  
On p age 3, in section Case 2 you didn't say what the dose of nivolumab was?  
Were the patients on any other medications that could cause colitis?  
Did you exclude infectious causes of colitis?  
Are the methods appropriate and well described?  
If not, please specify what is required in your comments to the authors.  
 
Yes 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in y our comments to the authors.  
 
Yes 
 
Are the conclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the manuscript or would you recommend an  
additional stat istical review?  
If an additional statistical review is recommended, please specify what aspects require further  
assessment in your comments to the editors.  
 
Not relevant to this manuscript  
 
  
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Acceptable  
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:  
 
1. Have you in the past five years received reimbursements, fees, funding, or salary from an  
organisation that may in any way gain or lose financially from the publication of this  
manuscript, either now or in the future?  
 
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose  
financi ally from the publication of this manuscript, either now or in the future?  
 
3. Do you hold or are you currently applying for any patents relating to the content of the  
manuscript?  
 
4. Have you received reimbursements, fees, funding, or sal ary from an organization that 
holds  or has applied for patents relating to the content of the manuscript?  
 
5. Do you have any other financial competing interests?  
 
6. Do you have any non -financial competing interests in relation to this paper?  
 
If you can ans wer no to all of the above, write 'I declare that I have no competing interests' 
below.  If your reply is yes to any, please give details below.  
 
I declare that I have no competing interests  
 
I agree to the open peer review policy of the journal. I understand  that my name will be included  
on my report to the authors and, if the manuscript is accepted for publication, my named report  
including any attachments I upload will be posted on the website along with the authors'  
responses. I agree for my report to be m ade available under an Open Access Creative Commons  
CC-BY license ( http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments  
which I do not wish to be included in my named report can be included as confidential comments  
to the editors, w hich will not be published.  
 
I agree to the open peer review policy of the journal